These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17276692)

  • 1. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain.
    Van Raamsdonk JM; Metzler M; Slow E; Pearson J; Schwab C; Carroll J; Graham RK; Leavitt BR; Hayden MR
    Neurobiol Dis; 2007 Apr; 26(1):189-200. PubMed ID: 17276692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
    Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
    BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models.
    Graham RK; Slow EJ; Deng Y; Bissada N; Lu G; Pearson J; Shehadeh J; Leavitt BR; Raymond LA; Hayden MR
    Neurobiol Dis; 2006 Feb; 21(2):444-55. PubMed ID: 16230019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Rogers DA; Bissada N; Vogl AW; Hayden MR; Leavitt BR
    Hum Mol Genet; 2005 May; 14(10):1379-92. PubMed ID: 15829505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo.
    Graham RK; Deng Y; Pouladi MA; Vaid K; Ehrnhoefer D; Southwell AL; Bissada N; Franciosi S; Hayden MR
    J Huntingtons Dis; 2012; 1(2):243-60. PubMed ID: 25063333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.
    Dorner JL; Miller BR; Barton SJ; Brock TJ; Rebec GV
    Behav Brain Res; 2007 Mar; 178(1):90-7. PubMed ID: 17239451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.
    Slow EJ; van Raamsdonk J; Rogers D; Coleman SH; Graham RK; Deng Y; Oh R; Bissada N; Hossain SM; Yang YZ; Li XJ; Simpson EM; Gutekunst CA; Leavitt BR; Hayden MR
    Hum Mol Genet; 2003 Jul; 12(13):1555-67. PubMed ID: 12812983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective degeneration in YAC mouse models of Huntington disease.
    Van Raamsdonk JM; Warby SC; Hayden MR
    Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background.
    Strong MK; Southwell AL; Yonan JM; Hayden MR; Macgregor GR; Thompson LM; Steward O
    J Huntingtons Dis; 2012; 1(2):221-41. PubMed ID: 23833693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice.
    Pouladi MA; Stanek LM; Xie Y; Franciosi S; Southwell AL; Deng Y; Butland S; Zhang W; Cheng SH; Shihabuddin LS; Hayden MR
    Hum Mol Genet; 2012 May; 21(10):2219-32. PubMed ID: 22328089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease.
    Van Raamsdonk JM; Pearson J; Slow EJ; Hossain SM; Leavitt BR; Hayden MR
    J Neurosci; 2005 Apr; 25(16):4169-80. PubMed ID: 15843620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin.
    Pouladi MA; Graham RK; Karasinska JM; Xie Y; Santos RD; Petersén A; Hayden MR
    Brain; 2009 Apr; 132(Pt 4):919-32. PubMed ID: 19224899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease.
    Carroll JB; Lerch JP; Franciosi S; Spreeuw A; Bissada N; Henkelman RM; Hayden MR
    Neurobiol Dis; 2011 Jul; 43(1):257-65. PubMed ID: 21458571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal analyses of operant performance on the serial implicit learning task (SILT) in the YAC128 Huntington's disease mouse line.
    Brooks SP; Jones L; Dunnett SB
    Brain Res Bull; 2012 Jun; 88(2-3):130-6. PubMed ID: 21763407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.
    Pouladi MA; Xie Y; Skotte NH; Ehrnhoefer DE; Graham RK; Kim JE; Bissada N; Yang XW; Paganetti P; Friedlander RM; Leavitt BR; Hayden MR
    Hum Mol Genet; 2010 Apr; 19(8):1528-38. PubMed ID: 20097678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
    Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
    FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
    Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
    J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.